NewAmsterdam Pharma (NAMS) to Release Quarterly Earnings on Wednesday

Key Points

• NewAmsterdam Pharma is expected to report its Q2 2025 earnings on August 6th, anticipating a loss of ($0.52) per share and revenue of $1.44 million.
• Analysts have given NewAmsterdam Pharma a consensus rating of "Moderate Buy" with a price target of $41.30, indicating a positive outlook from the market.
• Insider trading activity includes COO Douglas F. Kling selling over 51,000 shares while a director added to their holdings, reflecting contrasting views on the company's future.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.52) per share and revenue of $1.44 million for the quarter.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The business had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.53 during trading on Friday, hitting $21.28. 537,520 shares of the company's stock were exchanged, compared to its average volume of 776,378. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The business's 50-day simple moving average is $20.18 and its 200 day simple moving average is $20.04. The company has a market cap of $2.39 billion, a price-to-earnings ratio of -11.32 and a beta of -0.03.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a "buy" rating and a $44.00 target price for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $41.30.

Insider Buying and Selling

In related news, COO Douglas F. Kling sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the sale, the chief operating officer directly owned 44,000 shares of the company's stock, valued at approximately $848,760. This trade represents a 69.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper purchased 8,584 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were acquired at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the purchase, the director directly owned 3,022,153 shares in the company, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. 20.84% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 29,779 shares of the company's stock, valued at approximately $610,000. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.